购物车
- 全部删除
- 您的购物车当前为空
Voruciclib hydrochloride is an orally active and selective inhibitor of CDK (Ki: 0.626 nM-9.1 nM).
Voruciclib hydrochloride is an orally active and selective inhibitor of CDK (Ki: 0.626 nM-9.1 nM).
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5 mg | ¥ 8,190 | 5日内发货 | |
25 mg | 询价 | 5日内发货 | |
50 mg | 询价 | 5日内发货 | |
100 mg | 询价 | 5日内发货 |
产品描述 | Voruciclib hydrochloride is an orally active and selective inhibitor of CDK (Ki: 0.626 nM-9.1 nM). |
靶点活性 | CDK1-CyclinA:9.1 nM (ki), CDK6-CyclinD1:2.92 nM (ki), CDK9-CyclinT2:0.626 nM (ki), CDK1-CyclinB:5.4 nM (ki), CDK4-CyclinD1:3.96 nM (ki), CDK9-CyclinT1:1.68 nM (ki) |
体外活性 | In both ABC and GCB subtypes, Voruciclib hydrochloride (0.5-5 μM; 6 hours) shows targeted downregulation of MCL-1 . Ki values for each target such as CDK9/cyc T2, CDK9/cyc T1, CDK6/cyc D1, CDK4/cyc D1, CDK1/cyc B, and CDK1/cyc A for Voruciclib hydrochloride are 0.626 nM, 1.68 nM, 2.92 nM, 3.96 nM, 5.4 nM, 9.1 nM, respectively. |
体内活性 | Combination of Venetoclax (10 mpk, 1 mpk, 50 mpk, 25 mpk in U2932, RIVA, SU-DHL-4 and NU-DHL-1, respectively) and Voruciclib hydrochloride (200 mpk; Oral gavage) leads to enhance tumor growth inhibition compared to either drug alone in U2932, RIVA, SU-DHL-4 (six days per week for 4 weeks), and NU-DHL-1 models (five days per week for 3 weeks) of DLBCL. |
分子量 | 506.3 |
分子式 | C22H20Cl2F3NO5 |
CAS No. | 1000023-05-1 |
密度 | no data available |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 250 mg/mL (493.78 mM) | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容